3 results
To assess efficacy and safety of ivosidenib/enasidenib vs. placebo in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia (AML) or myelodysplastic…
The primary aim of the trial is to demonstrate the non-inferiority of CSL222 (formerly AMT-061) (2 × 1013 gc/kg) during the 52 weeks following establishment of stable factor IX expression (months 6 to 18) post-treatment (CSL222 (formerly AMT-061))…
Primary objectiveThe primary objective of this study is to compare the efficacy of EBRT versus SEMS insertion for palliation of malignant dysphagia in esophageal cancer patients at 4 weeks after start of treatment.Secondary objectivesSecondary…